Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (= 70 Years of Age)
Contact phone
Nurse - Tracy | 517.364.2835
Principal investigator
Dr. Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Hematology
Webform